EGFR and non-small cell lung carcinoma: Data show that the progression-free survival (PFS) of advanced NSCLC patients with sensitive EGFR mutations treated with EGFR-TKIs as the first-line treatment could reach 9.5-13.7 months, which is much longer than that achieved by traditional chemotherapy (4.6-6.9 months), and the overall efficiency rate of EGFR-TKIs was much higher than for traditional chemotherapy (58%-84% vs 15%-47%) [3–8].